ipamorelin clinical trials safety adverse effects What happens if an adult patient with no underlying severe ipamorelin clinical trials human studies
Description
Lu H, Wang L, Gao W, Meng J, Dai B, Wu S, Minna J, Roth JA, Hofstetter WL, Swisher SG , Fang B
[DOI] [PubMed] [Google Scholar] 301.Prema A., Janakiraman U., Manivasagam T., Thenmozhi A.J
Study parameter/endpoint Main study parameter/endpoint HAMD-17: The primary outcome criterion is the change in HAMD-17 score between the pre-treatment and the first post-treatment measurement
More recent clinical trials have found no difference in comparison to a placebo (Javed et al., 2015)
Does It Contain Harmful Preservatives
Must purchase BAC water for reconstitution
